Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 222

The DOI matches its Crossref record.

Altering the Progression of Human Alveolar Bone Loss With the Non‐Steroidal Anti‐Inflammatory Drug Flurbiprofen

Williams, Ray C., Jeffcoat, Marjorie K., Howard Howell, T., Rolla, Arturo, Stubbs, Derek, Teoh, Kok W., Reddy, Michael S., Goldhaber, Paul·1989·Journal of Periodontology

Abstract

T he treatment of human periodontal diseases relies on mechanical and antimicrobial suppression of the etiologic bacteria. The ability to alter the progression of Periodontitis by additionally blocking host pathways involved in the destructive process is an area of current research. Prostaglandins and other metabolites of arachidonic acid are believed to be important host mediators of the bone resorption of diseases such as Periodontitis. We have previously examined the effect of inhibitors of Prostaglandin production, non‐steroidal antiinflammatory drugs (NSAIDs), on inhibiting alveolar bone loss in beagles. The present study was designed to examine the effect of the NSAID, flurbiprofen, on slowing the radiographic loss of alveolar bone in the human. Fifty‐six individuals with radiographic evidence of alveolar bone loss were recruited for study. Forty‐four patients remained in the study for the data analysis of loss of alveolar bone. Following a 6 month baseline pretreatment period to measure the radiographic progression of bone loss, half of the patients were administered flurbiprofen, 50 mg. b.i.d., while half were administered a placebo. All patients received a subgingival scaling and pumice by a hygienist every 6 months. The rate of alveolar bone loss in a 2‐year treatment period was compared to the baseline 6 month pretreatment period within and between patient groups. Throughout the study, teeth exhibiting obvious loss of bone were exited from study and treated with conventional mechanical therapy. At the end of the pretreatment period both patient groups had a similar mean rate of alveolar bone loss. In individuals given placebo tablets, the rate of bone loss was significantly (P <.05) less than baseline at 6 and 12 months of treatment, but not thereafter. Individuals given flurbiprofen twice daily had a significant (P <.05) decrease in rate of bone loss compared to baseline at 6, 12 and 18 months of treatment. In addition we found that at 12 and 18 months of flurbiprofen use the rate of bone loss in the flurbiprofen treated individuals was significantly less than in the placebo patients. However at 24 months of the treatment period there was no difference in the rate of bone loss between the placebo and flurbiprofen treated patients. These data suggest that the NSAID flurbiprofen, as an inhibitor of cyclooxygenase, can inhibit human alveolar bone loss as measured radiographically. This finding suggests that pharmacologic agents whose main action is the blocking of host responses involved in the disease process may become adjuncts to anti‐infective therapy in the management of bone resorption diseases such as Periodontitis. (J Periodontol 1989;60:485–490)

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1902/jop.1989.60.9.485

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 222

Metadata

Authors
Williams, R. C., Jeffcoat, M. K., Howard Howell, T., Rolla, A., Stubbs, D., Teoh, K. W., Reddy, M. S., & Goldhaber, P.
Venue
Journal of Periodontology
Publisher
Wiley
Published
1989-09
Volume
60
Issue
9
Pages
485-490
ISSN
  • 0022-3492 (ISSN-L)
  • 1943-3670
OpenAlex
W2102925914
Cited by
222
References
0
FWCI
9.91
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Altering the Progression of Human Alveolar Bone Loss With the Non‐Steroidal Anti‐Inflammatory Drug Flurbiprofen. https://app.cochat.ai/papers/10.1902/jop.1989.60.9.485
The paper
Williams, R. C., Jeffcoat, M. K., Howard Howell, T., Rolla, A., Stubbs, D., Teoh, K. W., Reddy, M. S., & Goldhaber, P. (1989). Altering the Progression of Human Alveolar Bone Loss With the Non‐Steroidal Anti‐Inflammatory Drug Flurbiprofen. Journal of Periodontology. https://doi.org/10.1902/jop.1989.60.9.485

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.